GKOS:NYE-Glaukos Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 90.26

Change

+1.46 (+1.64)%

Market Cap

USD 1.10B

Volume

0.66M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 220.05B
MDT Medtronic PLC

N/A

USD 106.32B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 22.25B
STE STERIS plc

N/A

USD 22.15B
SNN Smith & Nephew SNATS Inc

N/A

USD 11.31B
PEN Penumbra Inc

N/A

USD 10.50B
GMED Globus Medical

N/A

USD 9.77B
BIO Bio-Rad Laboratories Inc

N/A

USD 6.94B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 6.39B
INSP Inspire Medical Systems Inc

N/A

USD 4.39B

ETFs Containing GKOS

WELL:PA HAN-GINS Indxx Healthcare.. 3.20 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.20 % 0.00 %

N/A

N/A
MWON:XETRA Amundi S&P SmallCap 600 E.. 1.01 % 0.00 %

N/A

N/A
USASUS:SW Amundi S&P SmallCap 600 E.. 0.84 % 0.00 %

N/A

USD 0.41B
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

N/A

USD 0.16B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

N/A

N/A
VIOG Vanguard S&P Small-Cap 60.. 0.00 % 0.20 %

N/A

USD 0.80B
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

N/A

N/A
ZSML:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

N/A

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 0.00 % 0.00 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.80% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.80% 14% F 4% F
Trailing 12 Months  
Capital Gain -5.12% 53% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.12% 53% F 27% F
Trailing 5 Years  
Capital Gain 152.90% 100% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 152.90% 100% F 82% B
Average Annual (5 Year Horizon)  
Capital Gain 32.27% 88% B+ 90% A-
Dividend Return 32.27% 88% B+ 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.20% 33% F 17% F
Risk Adjusted Return 63.02% 97% N/A 76% C+
Market Capitalization 1.10B 70% C- 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.30 24% 5%
Price/Book Ratio 7.54 21% 11%
Price / Cash Flow Ratio -94.27 100% 99%
Price/Free Cash Flow Ratio -57.89 100% 99%
Management Effectiveness  
Return on Equity -23.83% 59% 15%
Return on Invested Capital -16.29% 40% 13%
Return on Assets -7.06% 47% 11%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector